New Alzheimer Drugs: 2 from AAN '15 You Shouldn't Miss


These two new drugs for Alzheimer disease, presented at AAN 2015, are too good not to review. Here, a 6-slide summary of aducanumab and encenicline studies.

Outside of the cholinesterase inhibitors, the main class of drugs available to slow the cognitive decline of Alzheimer disease, patients and physicians have little choice of treatment.On stage at the 2015 American Academy of Neurology Annual conference in April, however, were results of 2 early-phase trials, one with a monoclonal antibody (phase 1B) found to reduce beta-amyloid plaque and the other with a nicotinic agonist (phase 2b) that improved both memory and cognitive function. Both posters generated cautious optimism about the future for AD patients.Click through the 6-slide summary above for study highlights.

Related Videos
video 4 - "Amyloid Cascade Hypothesis of Alzheimer’s Disease"
Video 3 - "Amyloid Precursor Protein and Amyloid Beta Species in Alzheimer’s Disease"
Anton P. Porsteinsson, MD
Lidia Maria Veras Rocha Moura, MD, PhD, MPH, FAAN
Tarun Singhal, MD, MBBS
Jessica Ailani, MD
© 2024 MJH Life Sciences

All rights reserved.